---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-014611"
form_type: "8-K"
ticker: "FEED"
cik: "0001326706"
company_name: "ENvue Medical, Inc."
filed_at: "2024-04-15T23:59:59+00:00"
generated_at: "2026-06-03T22:50:49.511489+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NanoVibronix receives Nasdaq delisting notice for bid price below $1.00

## Summary
- Nasdaq letter on April 10, 2024: common stock failed $1.00 minimum bid for 30 consecutive business days.
- Compliance period of 180 calendar days until October 7, 2024 to regain listing requirement.
- To cure, closing bid price must be $1.00 or more for at least 10 consecutive business days.
- If not cured, may be eligible for additional 180-day period if other listing standards are met.
- No immediate impact on trading; common stock continues to trade on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001493152-24-014611
- form_type: 8-K
- ticker: FEED
- cik: 0001326706
- company_name: ENvue Medical, Inc.
- filed_at: 2024-04-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326706/000149315224014611/0001493152-24-014611-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326706/000149315224014611/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-014611
- JSON: https://secwatch.observer/filing/0001493152-24-014611.json
- Plain text: https://secwatch.observer/filing/0001493152-24-014611.txt

## Key facts
- Listing & Compliance Notices
  ENvue Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: April 10, 2024, NanoVibronix, Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between February 27, 2024, to April 9, 2024, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2). The letter also indicated that the Company will be provided with a compliance period of 180 calendar days, or until Oc
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326706/000149315224014611/0001493152-24-014611-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.